Kite, A Gilead Company

This study tested a treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had returned or stopped responding after at least two prior treatments. The therapy works by reprogramming a patient's own immune cells…

This study tested a personalized cell therapy (axicabtagene ciloleucel) against standard treatments in 359 adults with relapsed/refractory diffuse large B-cell lymphoma. The therapy uses a patient's own immune cells, modified to attack cancer. The goal was to see if it delays dis…

This study tested a treatment called KTE-X19 (a CAR T-cell therapy) in 95 adults with mantle cell lymphoma that had come back or stopped responding to other treatments. The goal was to see how many patients had their tumors shrink or disappear. This is a disease-control approach,…

This study tested a cancer treatment called axicabtagene ciloleucel (a CAR T-cell therapy) given together with preventive steroids to 35 adults with relapsed or refractory large B-cell lymphoma. The goal was to see if this approach is safe and effective when given in an outpatien…

This study tested a treatment called KTE-X19 in 95 children and teens whose leukemia or lymphoma had returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, modified to better attack cancer cells. The goal was to see if it is safe an…